EVIDENCE-BASED PRACTICE (EBP)

Evidence-Based Practice
Name:
Institution:
Course code:
Date:
The healthcare industry is continuously looking for ways to improve the quality of patient care. Hospitals and organizations have transformative visions of making healthcare effective but easily accessible at a lower cost. They are also looking for new ways of reducing the health and economic burden of diseases. This essay focuses on Idiopathic pulmonary fibrosis (IPF) and its treatment options available at the moment through the analysis of Marilyn K. Glassberg's article.
The article describes Idiopathic pulmonary fibrosis (IPF) as a chronic and progressive disease that alters fibrosing interstitial lung functioning. Around three million people worldwide are affected by the disease, and the evidence is there because of the burden that the disease places on individuals and their families. Pulmonary fibrosis belongs to an ILD category that manages to cause lung damage through mechanisms such as inflammation, edema, or fibrosis. Patients' experiences differ once they have a diagnosis as most patients will slowly progress while others will have a rapid decline of the lungs. Therefore, it is difficult to predict the clinical course of an individual suffering from pulmonary fibrosis.
According to the article, age is a variable that goes hand in hand with a likelihood of a positive diagnosis. Pulmonary fibrosis is rare in individuals under 50; however, the chances increase with age. The case study involves a 76-year-old Caucasian woman diagnosed with the disease. Among persons aged 18 to 64, it is estimated that the annual incidence is six cases per 100,000 person-years. However, 65 years and older persons have an increased incidence of 94 per 100,000 p...